combin
unmanipul
haploident
hematopoiet
cell
transplant
cyclophosphamid
ptci
diseas
gvhd
prophylaxi
emerg
hct
strategi
produc
surviv
outcom
compar
human
leukocyt
antigen
hla
transplant
treatment
hematolog
malign
expand
donor
patient
undergo
receiv
bone
marrow
bm
graft
peripher
blood
stem
cell
pbsc
altern
graft
sourc
yield
higher
cell
count
obviat
need
donor
anesthesia
hematopoiet
cell
use
pbsc
graft
contain
cell
bm
graft
limit
concern
increas
gvhd
although
differ
gvhd
found
epidemiolog
incid
infecti
diseas
complic
associ
incomplet
understood
largest
studi
date
consist
patient
undergo
bm
report
moder
incid
cytomegaloviru
cmv
reactiv
peak
earli
period
bacteri
infect
highest
period
half
patient
least
one
bacteri
infect
donor
mrd
allogen
transplant
pbsc
graft
associ
increas
earli
cmv
decreas
rate
bacteri
fungal
compar
bm
graft
meanwhil
donor
allogen
transplant
pbsc
graft
associ
significantli
fewer
infecti
limit
inform
avail
concern
pbsc
studi
describ
epidemiolog
infecti
complic
associ
use
ptci
pbsc
graft
retrospect
cohort
includ
adult
age
patient
underw
pbsc
ptci
washington
univers
school
medicin
saint
loui
mo
june
june
patient
includ
regardless
diagnosi
data
collect
date
septemb
manual
review
electron
medic
record
studi
approv
washington
univers
school
medicin
institut
review
board
patient
receiv
peripher
mobil
hematopoiet
cell
graft
donor
select
hla
type
match
grade
rang
optim
donor
determin
order
lack
antibodi
recipi
cmv
serostatu
match
donor
health
statu
donor
mobil
granulocyt
factor
graft
cell
count
character
use
flow
cytometri
target
dose
cellskg
deplet
use
patient
receiv
mgkg
ptci
day
mycophenol
mofetil
either
tacrolimu
sirolimu
start
day
unless
contraind
patient
receiv
herpesviru
pneumocysti
fungal
prophylaxi
standard
herpesviru
prophylaxi
mg
acyclovir
three
time
day
tid
mg
valacyclovir
daili
qd
day
cessat
immunosuppress
patient
discharg
ganciclovir
gcv
cmv
treatment
transit
standard
herpesviru
prophylaxi
follow
complet
treatment
primari
fungal
prophylaxi
mg
fluconazol
qd
day
patient
histori
invas
fungal
infect
ifi
discharg
antifung
treatment
receiv
secondari
prophylaxi
continu
cessat
immunosuppress
pneumocysti
prophylaxi
given
day
consist
dapson
atovaquon
institut
patient
activ
screen
enterococcu
vre
colon
whole
blood
cmv
polymeras
chain
reaction
pcr
test
perform
twice
weekli
transplant
hospit
weekli
day
subsequ
monitor
determin
patient
physician
patient
receiv
antivir
treatment
cmv
diseas
consecut
doubl
blood
dna
level
pcr
signific
viremia
defin
iuml
approxim
equival
level
altern
pcr
assay
use
period
infecti
risk
defin
transplant
day
day
earli
day
late
neutrophil
engraft
defin
first
three
consecut
day
absolut
neutrophil
count
follow
nadir
platelet
engraft
defin
first
three
measur
within
day
show
without
platelet
transfus
previou
day
lymphopenia
defin
absolut
lymphocyt
count
acut
gvhd
agvhd
chronic
gvhd
cgvhd
defin
per
publish
caus
death
cod
determin
per
algorithm
copelan
et
neutropen
fever
defin
per
establish
infect
microbiolog
confirm
bacteri
isol
ident
suscept
pattern
consid
one
infect
obtain
within
day
regardless
sourc
blood
cultur
grow
bacteria
commonli
deem
skin
flora
consid
infect
verifi
second
posit
blood
cultur
cmv
infect
defin
detect
cmv
dna
pcr
cmv
reactiv
recurr
diseas
diagnos
accord
criteria
propos
ljungman
et
bk
polyomaviru
bkv
infect
consid
clinic
signific
bk
viruria
accompani
cystiti
without
clinic
explan
direct
fluoresc
antibodi
assay
andor
multiplex
pcr
assay
perform
nasopharyng
respiratori
specimen
use
diagnos
respiratori
viru
infect
consecut
posit
test
respiratori
pathogen
consid
singl
infect
unless
month
pass
sinc
previou
posit
test
ifi
report
accord
classif
propos
eortcmsg
consensu
proven
probabl
infect
includ
analysi
unless
note
infect
defin
accord
european
societi
bone
marrow
transplant
guidelin
ebmt
standard
descript
statist
use
character
studi
popul
evalu
distribut
variabl
none
variabl
interest
normal
distribut
median
rang
use
central
tendenc
dispers
continu
variabl
test
fisher
exact
test
appropri
use
evalu
distribut
categor
variabl
use
compar
distribut
continu
variabl
surviv
analysi
conduct
test
identifi
patient
inclus
studi
shown
tabl
cohort
contain
larg
number
patient
acut
myeloid
leukemia
common
diagnosi
percent
patient
receiv
previou
hct
activ
diseas
transplant
major
underw
one
three
previous
describ
condit
median
patient
day
rang
day
rang
surviv
patient
use
microbiolog
clinic
criteria
infect
diagnos
pathogen
summar
tabl
nineti
patient
neutropen
fever
within
day
transplant
patient
receiv
coverag
either
alreadi
receiv
agent
activ
staphylococcu
aureu
began
therapi
hour
onset
fever
patient
experienc
least
one
infect
median
onset
first
infect
day
rang
day
patient
sever
grade
agvhd
experienc
higher
number
bacteri
infect
median
rang
compar
patient
without
sever
agvhd
median
rang
patient
experienc
least
one
bacteri
viral
fungal
infect
respect
figur
parasit
infect
observ
median
time
first
infect
day
bacteri
day
viral
day
fungal
infect
incid
infect
per
subdivid
standard
period
infecti
risk
neutrophil
engraft
figur
b
diseas
associ
pathogen
class
summar
figur
overal
patient
experienc
total
bacteri
infect
period
mortal
significantli
higher
patient
experienc
least
one
bacteri
infect
figur
hazard
ratio
confid
interv
ci
enter
pathogen
respons
infect
occur
day
nearli
half
occur
day
common
site
associ
enter
organ
blood
urinari
tract
gastrointestin
tract
major
bloodstream
infect
bsi
prior
day
associ
mucos
barrier
injuri
central
venou
cathet
enterococcu
speci
respons
infect
enter
organ
gvhd
gut
associ
either
enterococcu
risk
ratio
rr
ci
enter
bacteri
infect
rr
ci
enterococc
infect
caus
vre
organ
patient
colon
vre
patient
develop
vre
infect
known
preced
enter
colon
number
significantli
higher
patient
develop
vre
infect
rr
ci
total
aureu
infect
identifi
skin
lung
blood
aureu
bsi
occur
patient
preced
skin
infect
overal
methicillin
resist
summar
tabl
thirteen
patient
develop
clostridium
difficil
infect
cdi
experienc
recurr
infect
interest
infect
within
week
transplant
three
patient
cdi
two
found
pancol
comput
tomographi
scan
anoth
colon
biopsi
consist
c
difficil
coliti
howev
three
patient
activ
gvhd
gut
etiolog
find
remain
unclear
one
patient
cdi
surviv
discharg
nine
infect
median
onset
day
rang
infect
day
occur
patient
diagnos
agvhd
cgvhd
gut
five
episod
treat
metronidazol
alon
eleven
episod
treat
oral
vancomycin
standard
cours
day
extend
one
patient
refractori
diseas
five
patient
also
receiv
intraven
metronidazol
patient
experienc
total
episod
cmv
viremia
median
onset
cmv
day
initi
infect
rang
day
day
overal
rang
day
recipi
cmv
serostatu
agvhd
associ
time
infect
episod
consid
reactiv
primari
infect
nineteen
episod
recurr
infect
none
follow
primari
infect
four
donor
neg
patient
experienc
primari
infect
compar
patient
median
group
day
respect
first
episod
cmv
viremia
compar
recurr
viremia
like
requir
treatment
vs
episod
rr
ci
initi
treatment
viremia
gcv
valgcv
episod
gcv
valgcv
episod
episod
resolv
without
treatment
episod
treat
multipl
medic
dosag
includ
foscarnet
immunoglobulin
four
patient
test
cmv
resist
treatment
failur
one
posit
mutat
gene
sixteen
patient
experienc
diseas
affect
gut
case
lung
case
case
one
case
involv
retina
mening
lung
first
episod
cmv
viremia
significantli
like
associ
cmv
diseas
vs
rr
ci
cmv
viremia
day
significantli
associ
cmv
diseas
vs
rr
ci
posit
recipi
cmv
serostatu
rr
ci
primari
infect
rr
ci
receiv
steroid
time
viremia
onset
rr
ci
receiv
mainten
dose
gcv
initi
therapi
rr
ci
significantli
associ
cmv
diseas
screen
patient
posit
herp
simplex
viru
hsv
antibodi
respect
hsv
reactiv
occur
seven
patient
six
patient
receiv
prophylact
dose
acyclovir
valacyclovir
time
reactiv
three
patient
present
oral
lesion
attack
rate
day
three
patient
present
genit
lesion
day
one
patient
present
mening
day
overal
attack
rate
later
develop
leg
genit
lesion
patient
hsv
reactiv
success
treat
surviv
discharg
observ
influenza
infect
patient
infect
occur
novemb
april
seven
patient
hospit
influenza
infect
five
treat
outpati
two
nosocomi
acquir
patient
gener
receiv
influenza
vaccin
start
day
begin
flu
season
whichev
later
institut
median
onset
infect
day
rang
three
infect
occur
day
four
infect
unvaccin
patient
occur
day
remain
seven
patient
three
becam
infect
despit
vaccin
patient
treat
mg
oseltamivir
twice
daili
bid
day
howev
four
hospit
patient
receiv
higher
dose
longer
treatment
base
acuiti
ill
patient
hospit
influenza
surviv
discharg
two
patient
respiratori
virus
one
parainfluenza
one
respiratori
syncyti
viru
rsv
test
viral
clearanc
perform
howev
none
nine
patient
receiv
subsequ
respiratori
viru
test
median
day
initi
infect
rang
still
shed
influenza
viru
two
five
patient
rsv
infect
present
lower
respiratori
tract
involv
defin
new
oxygen
requir
radiolog
find
consist
atyp
pneumonia
two
patient
along
one
patient
upper
respiratori
symptom
treat
nebul
ribavirin
g
tid
day
surviv
discharg
patient
rsv
infect
resolv
without
treatment
studi
period
patient
test
posit
bkv
urin
symptomat
infect
patient
record
experienc
hemorrhag
cystiti
grade
ii
grade
iii
grade
iv
percent
symptomat
patient
receiv
treatment
mg
ciprofloxacin
bid
treatment
defer
four
case
patient
prefer
wherea
two
patient
receiv
cidofovir
one
patient
receiv
continu
bladder
irrig
surviv
patient
median
absolut
lymphocyt
count
day
day
rang
rang
respect
cumul
incid
cmv
viremia
significantli
differ
patient
lymphopen
day
vs
vs
similarli
cumul
incid
respiratori
viru
infect
significantli
differ
patient
lymphopen
day
vs
vs
contrast
lymphopenia
day
day
associ
lower
cumul
incid
bk
cystiti
vs
vs
respect
seven
fungal
infect
diagnos
period
six
classifi
proven
accord
eortcmsg
via
blood
cultur
biopsi
autopsi
posit
blood
cultur
candida
zygomycet
speci
dissemin
mucormycosi
found
kidney
lung
one
patient
die
follow
stroke
patient
develop
fungal
infect
transplant
hospit
die
discharg
one
infect
classifi
probabl
galactomannan
assay
cavitari
nodul
chest
comput
tomographi
pneumocysti
infect
observ
nineteen
patient
discharg
initi
hospit
receiv
either
secondari
prophylaxi
voriconazol
therapeut
antifung
treatment
one
patient
later
develop
fungal
infect
period
patient
die
per
publish
common
primari
cod
relaps
follow
gvhd
primari
contribut
cod
period
infecti
risk
summar
tabl
infect
primari
cod
infect
contribut
cod
addit
fifteen
patient
microbiolog
diagnos
new
infect
within
day
death
patient
moder
agvhd
sever
agvhd
cgvhd
percent
infect
bacteri
viral
fungal
common
bacteri
pathogen
enterococcu
speci
bacilli
readmiss
rate
patient
surviv
discharg
readmiss
time
period
infect
primari
caus
analysi
describ
infecti
complic
patient
receiv
pb
ptci
overal
infect
primari
contribut
cod
half
patient
die
period
present
largest
publish
report
infecti
complic
patient
undergo
crocchiolo
et
analyz
cohort
patient
major
receiv
bm
graft
observ
establish
progress
infecti
agent
tradit
period
risk
bacteri
infect
peak
period
rate
approxim
per
viral
infect
promin
earli
period
occur
rate
per
observ
slightli
higher
rate
earli
bacteri
infect
markedli
higher
rate
earli
viral
infect
figur
note
patient
report
crocchiolo
et
receiv
routin
bacteri
prophylaxi
levofloxacin
wherea
median
time
neutrophil
engraft
shorter
vs
day
differ
may
skew
attribut
infect
period
despit
neutrophil
recoveri
particular
larg
number
viral
infect
occur
neutrophil
engraft
day
figur
vs
b
observ
rate
ifi
increas
earli
cmv
reactiv
consist
previou
literatur
compar
pbsc
bm
also
observ
high
incid
earli
neutropen
fever
cohort
associ
pb
fever
increasingli
recogn
high
incid
enterococc
infect
popul
notabl
find
colon
vre
associ
later
infect
consist
previous
publish
work
associ
enterococc
infect
earli
contrast
observ
aureu
infect
similar
previou
report
allogen
observ
rate
cdi
compar
previous
report
rate
rate
recurr
high
proport
cdi
report
associ
cdi
gastrointestin
gvhd
also
note
observ
cdi
discern
impact
surviv
role
graft
sourc
cmv
infect
still
matter
debat
mrd
set
young
et
found
differ
cmv
infect
within
larg
retrospect
cohort
patient
undergo
hct
either
bm
pbsc
howev
earli
cmv
reactiv
higher
rate
reactiv
diseas
patient
receiv
pbsc
graft
report
guerrero
et
analyz
cohort
mrd
patient
random
pbsc
bm
graft
found
alter
preval
prolifer
cell
follow
mobil
compar
previous
publish
data
bm
rate
cmv
viremia
associ
previou
donor
andor
recipi
cmv
seroposit
cmv
diseas
consider
higher
vs
vs
rate
cmv
viremia
among
seroposit
recipi
similar
anoth
cohort
pbsc
patient
vs
although
incid
cmv
diseas
consider
higher
vs
associ
earli
viremia
recipi
cmv
seroposit
cmv
diseas
consist
alter
cmv
immun
set
may
indic
need
altern
approach
treatment
cmv
viremia
popul
also
observ
rel
high
rate
hsv
prophylaxi
failur
especi
among
patient
seroposit
observ
low
rate
incid
ifi
cohort
similar
previous
report
rate
bm
low
rate
may
reflect
efficaci
receiv
extend
primari
antifung
prophylaxi
day
rel
larg
proport
patient
receiv
secondari
fungal
inclus
probabl
proven
fungal
infect
consist
literatur
like
result
underestim
true
incid
fungal
infect
popul
time
cohort
also
limit
may
also
contribut
underestim
fungal
infect
often
occur
later
patient
cgvhd
studi
sever
limit
first
exclud
suspect
infect
microbiolog
confirm
underestim
true
incid
infect
popul
febril
episod
identifi
organ
common
occurr
furthermor
mani
patient
suspect
pneumonia
undergo
bronchoscopi
owe
thrombocytopenia
howev
employ
strict
criteria
result
specif
reli
retrospect
clinic
judgment
second
studi
includ
comparison
group
make
contextu
report
rate
infect
difficult
especi
given
region
variat
pathogen
howev
also
allow
us
provid
extrem
broad
comprehens
descript
infecti
experi
within
novel
cohort
compar
studi
direct
futur
research
may
help
illumin
differ
immun
reconstitut
follow
compar
tradit
donor
third
limit
collect
data
medic
record
system
gener
patient
receiv
care
institut
case
acut
ill
patient
like
receiv
treatment
closer
home
episod
would
captur
studi
howev
patient
usual
transfer
institut
hospit
data
captur
overal
data
repres
conserv
estim
infecti
experi
popul
knowledg
cohort
repres
largest
analysi
infecti
complic
follow
ptci
present
literatur
also
first
detail
analysi
infecti
complic
patient
transplant
protocol
receiv
pbsc
graft
studi
need
compar
infecti
experi
patient
undergo
patient
undergo
hct
protocol
content
sole
respons
author
necessarili
repres
offici
view
nih
ms
sg
rr
sjl
design
studi
ms
sg
rr
jfd
erd
pw
glu
sjl
collect
data
ms
sjl
analyz
data
draft
articl
author
edit
approv
final
report
prior
submiss
